AnaMar is a drug discovery company developing orally bioavailable, peripherally acting 5-HT2B receptor antagonists. It centers on the prevention of pathological fibrotic processes. AnaMar’s drug pipeline includes a candidate for the treatment across a range of fibrotic diseases, with a focus on systemic sclerosis.